Telix Pharmaceuticals (NASDAQ:TLX) Hits New 1-Year Low – Here’s Why

Telix Pharmaceuticals Limited (NASDAQ:TLX) shares reached a new 52-week low during mid-day trading on Tuesday . The stock traded as low as $7.33 and last traded at $7.3550, with a volume of 22376 shares trading hands. The stock had previously closed at $7.55.

Wall Street Analyst Weigh In

Several research firms recently commented on TLX. Canaccord Genuity Group raised shares of Telix Pharmaceuticals to a “strong-buy” rating in a research note on Monday, October 6th. UBS Group reduced their target price on shares of Telix Pharmaceuticals from $23.00 to $20.00 and set a “buy” rating for the company in a report on Tuesday, September 23rd. Royal Bank Of Canada initiated coverage on Telix Pharmaceuticals in a research report on Monday, December 15th. They set a “hold” rating on the stock. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Telix Pharmaceuticals in a report on Wednesday, October 8th. Finally, Citigroup began coverage on shares of Telix Pharmaceuticals in a report on Thursday, September 18th. They issued a “buy” rating and a $22.00 target price on the stock. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $21.00.

Telix Pharmaceuticals Price Performance

The stock’s fifty day moving average is $8.86 and its 200-day moving average is $10.82.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Millennium Management LLC acquired a new stake in Telix Pharmaceuticals during the 3rd quarter worth $1,883,000. Pier Capital LLC purchased a new position in Telix Pharmaceuticals in the second quarter valued at about $3,037,000. Portland Investment Counsel Inc. acquired a new position in Telix Pharmaceuticals during the third quarter worth about $1,225,000. Lazard Asset Management LLC purchased a new position in Telix Pharmaceuticals during the third quarter worth $1,097,000. Finally, Russell Investments Group Ltd. purchased a new position in Telix Pharmaceuticals in the 2nd quarter valued at about $975,000.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals (NASDAQ: TLX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.